Minset Raises Funding to Scale AI Agent That Solves For Healthcare's $400B Revenue Cycle Problem
BOSTON, May 28, 2025 /PRNewswire/ -- Minset, the company behind the first multi-skilled agentic AI platform purpose-built for healthcare revenue cycle management, today announced a seed funding round led by HealthX Ventures, a leading digital health venture firm. The funding will accelerate product development and scale go-to-market efforts as Minset expands its platform to more healthcare organizations worldwide.
As part of this next phase of growth, Minset also announced the appointment of Mike Luessi to lead Growth & Operations. Luessi joins CEO Trey McMillian and CTO Matt Scott, bringing more than 20 years of experience building and scaling high-growth companies. This rounds out an experienced leadership team with deep expertise at the intersection of AI R&D, and scaling complex platforms in healthcare and enterprise technology.
'The investment from HealthX and the addition of Mike to our team accelerates our mission to fix one of healthcare's toughest financial challenges: Revenue Cycle Management,' said Trey McMillian, CEO of Minset. 'We built Minset to end the chaos, not manage it. Our agentic AI platform doesn't just track revenue work, it does the work. Mia, our multi-skilled AI agent thinks, reasons, and acts to get healthcare organizations paid.'
Meet Mia: Multi-Skilled Agentic AI That Gets Healthcare Paid
Minset is pioneering a new category in healthcare operations: the Autonomous Revenue Cycle (ARC). At the heart of the platform is Mia, Minset's intelligent, multi-skilled agentic AI. Unlike other platforms that rely on a complex mix of orchestrated single-skilled agents and other tools, Mia handles it all. From coding and denials to payments, Mia's got it – no bots to wrangle nor micromanagement required.
Mia learns, reasons and resolves revenue cycle issues quickly, helping providers prevent denials, recover revenue, and operate at scale. She works 24/7 and continuously evolves to keep up with payer rules, regulatory shifts, and operational complexity.
Helping over 300 healthcare organizations to date, Mia powers three core products: mCoder to automate medical coding, mDenials to manage denials, and m360 for patient engagement (propensity to pay).
From hospitals and clinics trying to get paid for the care they provide, to insurers overwhelmed by administrative burden, Mia brings intelligence, speed, fairness, and transparency to healthcare finance.
'We are thrilled to partner with Minset to create cutting-edge AI technology to transform healthcare operations,' said Jan Grimm, CEO of Savista, a leading healthcare revenue cycle management services company. 'Our combined expertise will empower healthcare organizations with smarter, faster, and more efficient revenue cycle solutions. By partnering on AI solutions, including AI agents, we are poised to modernize the RCM space, delivering unprecedented value to healthcare providers.'
HealthX Ventures, known for investing in companies modernizing healthcare infrastructure, sees Minset as a step-change in the application of AI to healthcare financial operations.
'Minset isn't automation, it's autonomy,' said Kristi Ebong, Partner at HealthX Ventures. 'This is the first platform we've seen that truly replaces the manual work of the revenue cycle, without requiring providers to rip and replace their core systems. The team is solving a real problem with real AI, and the traction speaks for itself.'
'Traditional systems have hit their ceiling. Minset gives healthcare a new ceiling—or better yet, removes it. It delivers clarity where there was chaos, and outcomes where there were only excuses. They're building what could become the most important financial infrastructure company in healthcare,' said Ebong.
The Minset Platform integrates seamlessly with major EHR and claim workflow systems, replacing spreadsheets, queues, and legacy processes, with a multi-skilled AI agent who's always on, always improving, and always delivering outcomes.
To learn more, visit www.minset.ai
Media Contact: Mike Luessi [email protected]
About Minset
Minset created the first multi-skilled agentic AI platform purpose-built for healthcare revenue cycle management. Designed to think, reason, and act across the entire revenue lifecycle, Minset's platform helps healthcare organizations get paid, automatically, accurately, and at scale. Its suite of intelligent products: mCoder for autonomous medical coding, mDenials for denials management, and m360 for patient engagement, replaces manual work and fragmented tools with one, state-of-the-art agentic AI system. Founded by experts from Google, Microsoft, Optum and Salesforce, and backed by HealthX Ventures, Minset is helping providers reclaim time, reduce burnout, and achieve financial clarity in an increasingly complex environment. To learn more, visit www.minset.ai.
About HealthX Ventures
HealthX Ventures is a digital health-focused venture capital firm investing in companies that make healthcare more efficient, affordable, and accessible. The firm partners with founders building scalable, enterprise-grade technology solutions that move the industry forward. Learn more at www.healthxventures.com.
View original content to download multimedia: https://www.prnewswire.com/news-releases/minset-raises-funding-to-scale-ai-agent-that-solves-for-healthcares-400b-revenue-cycle-problem-302466156.html
SOURCE MInset AI, Inc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Three-year-old from Chillicothe diagnosed with cancer; family asks for help
CHILLICOTHE ― Shocking news hit the Allison family on June 1, when something they never thought was possible happened: their three-year-old son, Brandon Jr, was diagnosed with Stage IV Wilms Tumor cancer. Now the family is asking for help with a GoFundMe to help with the ever-growing medical bills that come with a cancer diagnosis, Brandon's mother, Larisa Allison, said. Allison said Wilms Tumor is a rare kidney cancer that affects mainly children. "He had a five-inch tumor on his kidney," Allison said. "They did a couple weeks of chemo before they took out his tumor and his kidney out." Allison said the whole situation has been overwhelming. "He was a perfect, healthy baby boy," Allison said. "Nothing ever wrong with him, nothing ever even bothered him. Chemo isn't even bothering him. He's still crazy, running around right after chemo, like nothing's ever happened to him. He says he's not sick." Allison said her husband has not been able to go to work since his son's first surgery in early July. "My son's first surgery was July 24, so he got that and he healed for a couple of weeks," Allison said. "Then he also had another surgery, where they cut a little piece out of his ling because their was a little nodule in it." The GoFundMe will help Brandon's family pay hospital bills during this time, as he undergoes more chemotherapy and radiation. This article originally appeared on Chillicothe Gazette: Chillicothe family starts GoFundMe for three year old with cancer Solve the daily Crossword
Yahoo
7 minutes ago
- Yahoo
Tech stocks slip as investors rotate towards defensive sectors
A decline in US tech stocks extended into Wednesday as concerns about the durability of this year's rally in artificial intelligence shares Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Goldman Traders Say It's Time to Buy the Dip in Momentum Stocks
(Bloomberg) -- Sharp losses in high-flying momentum stocks may present a dip-buying opportunity if history is any guide, according to Goldman Sachs Group Inc.'s trading desk. The traders cited rebounds after similar prior losses in Goldman's High Beta Momentum basket, coupled with the current technical setup. Why New York City Has a Fleet of New EVs From a Dead Carmaker Trump Takes Second Swing at Cutting Housing Assistance for Immigrants Chicago Schools Seeks $1 Billion of Short-Term Debt as Cash Gone Neom's Desert Ski Resort Strains Saudi Prince's $1.5 Trillion Plan When the long-short momentum basket dropped 10% or more over a five-day span in the past, it proceeded to rise in the following week 80% of the time, the traders wrote in a note to clients on Tuesday. The median return was 4.5% in the next week and more than 11% in the next month. The sudden unwind in the momentum strategy, which focuses on buying recent winners and selling short those that are lagging behind, first came amid a rally in the basket's stocks meant to be shorted. But its declines this week were powered more by losses in the long leg of the basket 'as themes such as AI feel the pain of this rotation,' Goldman's traders wrote. The basket fell 13% from Aug. 6 through Aug. 19 after trading near an all-time high. The traders also parsed through technical charts for clues on what could stop the selloff in the momentum trade. The momentum basket is trading near an oversold territory and is approaching the bottom of its so-called regression channel, which is basically the lower boundary of an existing trend. The basket also fell below its 200-day moving average, the level that could serve as a major support. 'It could be a good entry point into the historically rewarded factor, unless tech earnings next week drive a prolonged AI selloff,' Goldman's traders wrote. Nvidia Corp., the biggest member in both the S&P 500 and Nasdaq 100 indexes, is scheduled to release its quarterly results on Aug. 27. Some of the stock market's biggest losers in the past three days include Palantir Technologies Inc., which fell 12%, and Advanced Micro Devices Inc. and Super Micro Computer Inc., which lost 6% or more. Nvidia fell just 2.8% during that time, but its heavy weighting in benchmark indexes made it a drag on the market. Those stocks 'were among the year's most crowded trades, built on optimism toward AI and speculative momentum, making them vulnerable to swift reversals,' Chris Murphy, co-head of derivatives strategy at Susquehanna International Group, wrote in a note. The selloff in the momentum factor, which includes high-flying AI stocks on the long side of the basket, comes amid a variety of concerns in the market including soaring valuations, stretched positioning and increasing competition from China. The Nasdaq 100 Index is trading at 27 times expected 12-month profits, almost a third above its long-term average. Meanwhile, China's warnings to tech firms to avoid one of Nvidia's chips and a drop in cloud-computing company CoreWeave Inc.'s shares after its earnings report were among other recent headwinds to momentum stocks. Another source of concern for tech investors cropped up this week as a Massachusetts Institute of Technology report found that most generative AI initiatives implemented to drive revenue growth are falling flat and only 5% of generative AI pilots are delivering profit. Still, this isn't the only stumble for Goldman's High-Beta Momentum basket this year: This is its fourth retreat of more than 10% in 2025. 'The recent decline in momentum is indicative of how the factor has been trading all year. It's been a frustrating and choppy trade through all of 2025,' said Bloomberg Intelligence's Christopher Cain. 'While the recent decline could be a tactical opportunity, we also point out that that high momentum stocks are showing some of the most expensive valuations compared to low momentum in history.' Foreigners Are Buying US Homes Again While Americans Get Sidelined What Declining Cardboard Box Sales Tell Us About the US Economy Survived Bankruptcy. Next Up: Cultural Relevance? Women's Earnings Never Really Recover After They Have Children Americans Are Getting Priced Out of Homeownership at Record Rates ©2025 Bloomberg L.P. Sign in to access your portfolio
